---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106536"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:30:56.445542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M

## Summary
- Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.
- Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.
- Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.
- Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.
- New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized.

## SEC filing metadata
- accession: 0000950170-25-106536
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/0000950170-25-106536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/qncx-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106536
- JSON: https://secwatch.observer/filing/0000950170-25-106536.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.